meloxicam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory, isoxicam derivatives 1676 71125-38-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • reumoxicam
  • miloxicam
  • meloxicam
  • metacam
  • meloxicam sodium
  • meloxicam sodium hydrate
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of meloxicam, like that of other NSAIDs, may be related to prostaglandin synthetase (cyclo-oxygenase) inhibition.
  • Molecular weight: 351.40
  • Formula: C14H13N3O4S2
  • CLOGP: 2.44
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 99.60
  • ALOGS: -3.36
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
15 mg P
15 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 0.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.71 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 97 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 18 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 13, 2000 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rheumatoid arthritis 229.85 10.02 940 105897 252879 63129306
Synovial cyst 200.24 10.02 155 106682 10278 63371907
Ankylosing spondylitis 163.69 10.02 138 106699 10336 63371849
Spinal column injury 156.31 10.02 74 106763 1977 63380208
Fibromyalgia 152.11 10.02 384 106453 80036 63302149
Surgical failure 147.40 10.02 57 106780 909 63381276
Bronchitis chronic 135.65 10.02 87 106750 4266 63377919
Psoriatic arthropathy 135.12 10.02 399 106438 91121 63291064
Death 126.80 10.02 276 106561 374105 63008080
Tenosynovitis 124.19 10.02 134 106703 13661 63368524
Joint range of motion decreased 121.00 10.02 205 106632 32223 63349962
Pulmonary toxicity 118.64 10.02 110 106727 9345 63372840
Reversible airways obstruction 117.94 10.02 59 106778 1783 63380402
Vital capacity decreased 115.53 10.02 57 106780 1671 63380514
Musculoskeletal stiffness 113.36 10.02 611 106226 184007 63198178
Accident 110.09 10.02 87 106750 5945 63376240
Sputum culture positive 108.90 10.02 59 106778 2108 63380077
Febrile neutropenia 107.10 10.02 33 106804 118416 63263769
Psoriasis 106.16 10.02 355 106482 86602 63295583
Crepitations 105.67 10.02 96 106741 7944 63374241
Tenosynovitis stenosans 104.24 10.02 67 106770 3297 63378888
Musculoskeletal pain 101.58 10.02 364 106473 91913 63290272
Bone density decreased 101.27 10.02 124 106713 14488 63367697
Synovial fluid analysis 97.22 10.02 57 106780 2376 63379809
Neutropenia 94.49 10.02 93 106744 174912 63207273
Bronchial secretion retention 92.84 10.02 58 106779 2715 63379470
Allergy to chemicals 92.82 10.02 60 106777 2982 63379203
Neck pain 89.99 10.02 289 106548 69029 63313156
Dry eye 87.03 10.02 204 106633 40557 63341628
Drug hypersensitivity 86.92 10.02 851 105986 309836 63072349
Exposure during pregnancy 85.89 10.02 81 106756 155466 63226719
Arthralgia 83.70 10.02 1384 105453 568326 62813859
Maternal exposure during pregnancy 81.41 10.02 154 106683 219908 63162277
Scleritis 81.10 10.02 64 106773 4364 63377821
Bursitis 79.75 10.02 186 106651 36855 63345330
Pemphigus 78.65 10.02 117 106720 183609 63198576
Pain in extremity 76.76 10.02 874 105963 330612 63051573
Visual impairment 75.61 10.02 312 106525 84134 63298051
Antinuclear antibody positive 74.29 10.02 79 106758 7920 63374265
Rheumatoid lung 71.30 10.02 56 106781 3792 63378393
Hypotension 70.88 10.02 229 106608 272375 63109810
Dry mouth 70.75 10.02 289 106548 77574 63304611
Toxicity to various agents 69.05 10.02 201 106636 247049 63135136
Breast cancer 66.72 10.02 206 106631 48177 63334008
Product dose omission issue 66.54 10.02 644 106193 233669 63148516
Linear IgA disease 66.02 10.02 37 106800 1414 63380771
Neck surgery 65.05 10.02 40 106797 1820 63380365
Glossodynia 63.69 10.02 128 106709 178748 63203437
Sciatica 59.81 10.02 159 106678 34165 63348020
Gait disturbance 59.34 10.02 518 106319 182660 63199525
Off label use 56.41 10.02 798 106039 673664 62708521
Pleuritic pain 55.41 10.02 68 106769 7961 63374224
Deep vein thrombosis postoperative 53.61 10.02 80 106757 11289 63370896
Cushingoid 52.42 10.02 68 106769 8417 63373768
Thrombocytopenia 52.25 10.02 110 106727 151047 63231138
Photophobia 51.18 10.02 100 106737 17535 63364650
Viral upper respiratory tract infection 51.03 10.02 64 106773 7660 63374525
Impaired work ability 50.61 10.02 99 106738 17376 63364809
Feeling jittery 50.35 10.02 85 106752 13318 63368867
Systemic lupus erythematosus 49.21 10.02 183 106654 208735 63173450
Autoimmune disorder 48.16 10.02 96 106741 17081 63365104
Malignant neoplasm progression 47.42 10.02 41 106796 82080 63300105
Cardiac failure 47.36 10.02 48 106789 89094 63293091
Anaemia 47.00 10.02 295 106542 293135 63089050
Nodule 46.82 10.02 107 106730 20919 63361266
Upper-airway cough syndrome 46.37 10.02 75 106762 11343 63370842
Joint effusion 46.22 10.02 94 106743 16966 63365219
Disease progression 46.16 10.02 85 106752 122673 63259512
Back pain 46.01 10.02 661 106176 263484 63118701
Pulmonary mass 44.90 10.02 110 106727 22486 63359699
Joint swelling 43.94 10.02 785 106052 326881 63055304
Muscular weakness 43.30 10.02 353 106484 122000 63260185
Conjunctivitis 43.21 10.02 103 106734 20693 63361492
Septic shock 42.60 10.02 30 106807 66599 63315586
Rheumatoid nodule 42.37 10.02 91 106746 17064 63365121
Osteoarthritis 42.19 10.02 290 106547 95053 63287132
Multiple allergies 42.18 10.02 80 106757 13722 63368463
Pancytopenia 42.17 10.02 61 106776 96872 63285313
Flank pain 41.62 10.02 88 106749 16322 63365863
Tenderness 40.77 10.02 106 106731 22472 63359713
Drug abuse 39.73 10.02 38 106799 72480 63309705
Peripheral swelling 39.58 10.02 648 106189 265294 63116891
Premature delivery 39.47 10.02 3 106834 30278 63351907
Abortion spontaneous 39.44 10.02 15 106822 47180 63335005
Acute kidney injury 39.06 10.02 271 106566 263144 63119041
Ocular hyperaemia 38.39 10.02 111 106726 25033 63357152
Pyrexia 37.71 10.02 561 106276 469917 62912268
Hypoaesthesia 37.10 10.02 440 106397 167953 63214232
Drug ineffective 37.09 10.02 2128 104709 1042637 62339548
Eosinophil count increased 36.74 10.02 66 106771 10862 63371323
Eye irritation 35.50 10.02 99 106738 21872 63360313
Listless 35.35 10.02 33 106804 2827 63379358
General physical health deterioration 35.13 10.02 197 106640 201205 63180980
Intervertebral disc degeneration 34.96 10.02 80 106757 15652 63366533
Deformity 34.82 10.02 67 106770 11617 63370568
Pleural effusion 34.63 10.02 65 106772 93145 63289040
Grip strength decreased 34.62 10.02 99 106738 22188 63359997
Infection 33.93 10.02 558 106279 228615 63153570
Feeling abnormal 33.24 10.02 389 106448 148003 63234182
Somatic delusion 32.23 10.02 17 106820 575 63381610
Condition aggravated 32.12 10.02 895 105942 401322 62980863
Loss of personal independence in daily activities 31.92 10.02 276 106561 97014 63285171
Road traffic accident 31.72 10.02 134 106703 36498 63345687
Gait inability 31.58 10.02 174 106663 52785 63329400
Depression 31.56 10.02 485 106352 196007 63186178
C-reactive protein 31.54 10.02 40 106797 4842 63377343
Cholestasis 30.87 10.02 6 106831 29428 63352757
Drug interaction 30.48 10.02 243 106594 228888 63153297
Arthritis 30.14 10.02 313 106524 115608 63266577
Injection site pain 29.84 10.02 342 106495 129458 63252727
Gastric ulcer 29.19 10.02 98 106739 23939 63358246
Hyponatraemia 29.04 10.02 94 106743 111806 63270379
Malaise 28.45 10.02 908 105929 415046 62967139
Rash pruritic 28.31 10.02 185 106652 59614 63322571
Intentional self-injury 27.45 10.02 5 106832 25682 63356503
Atelectasis 27.35 10.02 89 106748 21394 63360791
Eye pain 27.14 10.02 121 106716 33733 63348452
Ischaemic gastritis 26.95 10.02 5 106832 0 63382185
Injection site swelling 26.84 10.02 154 106683 47418 63334767
Sedation 26.81 10.02 16 106821 38793 63343392
Intentional overdose 26.42 10.02 53 106784 74099 63308086
Electrocardiogram QT prolonged 26.34 10.02 37 106800 59493 63322692
Infusion related reaction 26.31 10.02 275 106562 245246 63136939
Surgery 26.30 10.02 125 106712 35787 63346398
Respiratory failure 26.13 10.02 86 106751 101772 63280413
Reduced facial expression 24.91 10.02 23 106814 1943 63380242
Wound 24.65 10.02 167 106670 163096 63219089
Spinal cord infection 24.64 10.02 15 106822 670 63381515
Premature baby 24.54 10.02 3 106834 20732 63361453
Myelosuppression 24.51 10.02 5 106832 23698 63358487
Sputum culture 24.36 10.02 11 106826 263 63381922
Lymphomatoid papulosis 24.34 10.02 9 106828 126 63382059
Pre-existing condition improved 24.23 10.02 47 106790 8197 63373988
Hepatic enzyme increased 24.03 10.02 221 106616 202107 63180078
HLA marker study positive 23.65 10.02 10 106827 203 63381982
Anxiety 23.64 10.02 505 106332 217036 63165149
Injury 23.61 10.02 207 106630 73040 63309145
Liver disorder 23.56 10.02 163 106674 53524 63328661
Multiple organ dysfunction syndrome 23.43 10.02 37 106800 56715 63325470
Lung disorder 23.31 10.02 182 106655 62079 63320106
Lower limb fracture 22.86 10.02 91 106746 24130 63358055
Neoplasm malignant 22.65 10.02 105 106732 29756 63352429
Rash maculo-papular 22.62 10.02 110 106727 31786 63350399
Foetal exposure during pregnancy 22.33 10.02 13 106824 31949 63350236
Platelet count decreased 22.23 10.02 110 106727 116012 63266173
Pericarditis 22.23 10.02 130 106707 131449 63250736
Drug intolerance 22.19 10.02 678 106159 307983 63074202
Blood creatinine increased 21.96 10.02 75 106762 87769 63294416
Injection site vesicles 21.83 10.02 26 106811 2951 63379234
Musculoskeletal discomfort 21.59 10.02 73 106764 17894 63364291
Interstitial lung disease 21.56 10.02 178 106659 61730 63320455
Blood cholesterol increased 21.26 10.02 247 106590 93785 63288400
Eosinophilia 21.18 10.02 6 106831 22750 63359435
Agranulocytosis 20.98 10.02 8 106829 25126 63357059
Gastric ulcer haemorrhage 20.97 10.02 33 106804 4875 63377310
Mobility decreased 20.97 10.02 303 106534 120856 63261329
Mucosal inflammation 20.93 10.02 29 106808 46899 63335286
Adjustment disorder with depressed mood 20.62 10.02 50 106787 10154 63372031
Lip dry 20.52 10.02 65 106772 15405 63366780
Head discomfort 20.26 10.02 59 106778 13356 63368829
Prescribed overdose 20.21 10.02 112 106725 34041 63348144
Memory impairment 20.19 10.02 266 106571 103992 63278193
Bradycardia 20.06 10.02 60 106777 73167 63309018
X-ray abnormal 20.00 10.02 43 106794 8067 63374118
Oesophageal mucosal tear 19.80 10.02 5 106832 16 63382169
Hypermobility syndrome 19.77 10.02 14 106823 809 63381376
Suicide attempt 19.67 10.02 46 106791 60872 63321313
Fixed eruption 19.56 10.02 16 106821 1148 63381037
Injection site erythema 19.49 10.02 220 106617 82954 63299231
Spinal operation 19.43 10.02 43 106794 8228 63373957
Wheezing 19.39 10.02 246 106591 95349 63286836
Hepatocellular injury 19.33 10.02 11 106826 27370 63354815
Leukopenia 19.31 10.02 66 106771 77224 63304961
Eyelid retraction 19.23 10.02 6 106831 48 63382137
Pulmonary arterial hypertension 19.16 10.02 7 106830 22570 63359615
Anti-cyclic citrullinated peptide antibody positive 19.00 10.02 116 106721 116096 63266089
Ejection fraction decreased 18.82 10.02 7 106830 22325 63359860
Poliomyelitis 18.81 10.02 6 106831 52 63382133
Cataract 18.78 10.02 162 106675 56891 63325294
Neutrophil count decreased 18.69 10.02 42 106795 56364 63325821
Pain 18.38 10.02 1465 105372 739163 62643022
Neutropenic sepsis 18 10.02 3 106834 16435 63365750
C-reactive protein abnormal 17.95 10.02 136 106701 45960 63336225
Carpal tunnel syndrome 17.90 10.02 76 106761 20741 63361444
Hypoxia 17.86 10.02 47 106790 59745 63322440
Hypercalcaemia 17.78 10.02 13 106824 28309 63353876
Nodular rash 17.50 10.02 8 106829 197 63381988
Sepsis 17.43 10.02 169 106668 152954 63229231
Hepatic cirrhosis 17.37 10.02 10 106827 24724 63357461
Obstructive airways disorder 17.36 10.02 75 106762 20624 63361561
Posterior reversible encephalopathy syndrome 17.24 10.02 4 106833 17341 63364844
Respiratory distress 17.22 10.02 19 106818 33932 63348253
Gastric mucosal hypertrophy 17.22 10.02 6 106831 70 63382115
Small intestinal ulcer haemorrhage 17.22 10.02 6 106831 70 63382115
Vertigo 17.15 10.02 165 106672 59722 63322463
Product use in unapproved indication 17.03 10.02 206 106631 178874 63203311
Upper respiratory tract infection 17.01 10.02 212 106625 81835 63300350
Swelling 16.97 10.02 344 106493 275034 63107151
Acute myeloid leukaemia 16.95 10.02 4 106833 17143 63365042
Tachycardia 16.78 10.02 123 106714 118033 63264152
Product use issue 16.58 10.02 266 106571 220254 63161931
Body temperature increased 16.57 10.02 23 106814 37169 63345016
Foreign body 16.46 10.02 20 106817 2318 63379867
Bone marrow failure 16.45 10.02 15 106822 29275 63352910
Clostridium difficile colitis 16.43 10.02 7 106830 20562 63361623
Delirium 16.37 10.02 143 106694 50398 63331787
Injection site reaction 16.15 10.02 160 106677 58364 63323821
Respiratory tract infection 15.93 10.02 122 106715 41361 63340824
Urine odour abnormal 15.90 10.02 34 106803 6355 63375830
Affect lability 15.85 10.02 48 106789 11103 63371082
International normalised ratio increased 15.85 10.02 34 106803 46391 63335794
Swelling face 15.83 10.02 170 106667 63305 63318880
Oedema peripheral 15.82 10.02 224 106613 189287 63192898
Pneumonia aspiration 15.75 10.02 21 106816 34519 63347666
Ulcer 15.71 10.02 86 106751 26021 63356164
Intervertebral disc protrusion 15.56 10.02 80 106757 23629 63358556
Spinal osteoarthritis 15.43 10.02 61 106776 16125 63366060
Cytomegalovirus infection 15.40 10.02 8 106829 20944 63361241
Synovial disorder 15.22 10.02 18 106819 2027 63380158
Demyelination 15.17 10.02 35 106802 6885 63375300
Hyperkalaemia 15.15 10.02 44 106793 54159 63328026
Hepatic failure 14.95 10.02 23 106814 35633 63346552
Parotid gland enlargement 14.86 10.02 12 106825 846 63381339
Injection site bruising 14.86 10.02 121 106716 41789 63340396
Nephrolithiasis 14.77 10.02 121 106716 41863 63340322
Anhidrosis 14.65 10.02 6 106831 112 63382073
Wound infection 14.58 10.02 73 106764 21337 63360848
Rhabdomyolysis 14.34 10.02 33 106804 43918 63338267
Dysphoria 14.22 10.02 28 106809 4938 63377247
Device expulsion 14.20 10.02 23 106814 34899 63347286
Walking aid user 14.19 10.02 45 106792 10672 63371513
Sacroiliitis 14.06 10.02 22 106815 3235 63378950
Trigger finger 14.03 10.02 26 106811 4382 63377803
Stress fracture 13.98 10.02 37 106800 7926 63374259
Creatinine renal clearance decreased 13.93 10.02 5 106832 16303 63365882
Therapy cessation 13.67 10.02 93 106744 30364 63351821
Symptom recurrence 13.59 10.02 16 106821 1794 63380391
Duodenal ulcer 13.58 10.02 36 106801 7720 63374465
Lumbar spinal stenosis 13.58 10.02 27 106810 4795 63377390
Porphyria acute 13.44 10.02 13 106824 1164 63381021
Dyspnoea exertional 13.42 10.02 54 106783 60248 63321937
Metastases to liver 13.40 10.02 12 106825 23627 63358558
Small intestine ulcer 13.31 10.02 8 106829 349 63381836
Kyphoscoliosis 13.30 10.02 9 106828 483 63381702
Pelvic fracture 13.29 10.02 51 106786 13297 63368888
Thalassaemia minor 13.16 10.02 4 106833 29 63382156
Proteinuria 13.08 10.02 8 106829 19137 63363048
Prescription drug used without a prescription 13.02 10.02 18 106819 2368 63379817
Spinal fusion surgery 12.93 10.02 29 106808 5599 63376586
Limb asymmetry 12.76 10.02 11 106826 849 63381336
Hepatotoxicity 12.75 10.02 27 106810 37014 63345171
Swollen joint count increased 12.73 10.02 104 106733 35950 63346235
Knee operation 12.73 10.02 30 106807 5983 63376202
Head titubation 12.67 10.02 11 106826 857 63381328
Red blood cell sedimentation rate abnormal 12.52 10.02 9 106828 19773 63362412
Impaired gastric emptying 12.43 10.02 42 106795 10290 63371895
Colitis 12.42 10.02 41 106796 48487 63333698
Dyspnoea 12.35 10.02 952 105885 660361 62721824
Coma 12.30 10.02 61 106776 64303 63317882
Pharyngeal paraesthesia 12.25 10.02 16 106821 1993 63380192
Dysstasia 12.25 10.02 69 106768 21097 63361088
Purpura senile 12.21 10.02 9 106828 554 63381631
Ascites 12.17 10.02 32 106805 40696 63341489
Jaundice neonatal 12.07 10.02 11 106826 914 63381271
Pulmonary hypertension 12.01 10.02 28 106809 37095 63345090
Syncope 11.94 10.02 133 106704 117252 63264933
Myofascial pain syndrome 11.93 10.02 17 106820 2301 63379884
Orthostatic hypotension 11.92 10.02 27 106810 36133 63346052
Cardiac failure congestive 11.83 10.02 99 106738 92334 63289851
Cerebral haemorrhage 11.79 10.02 21 106816 30708 63351477
Distributive shock 11.69 10.02 13 106824 1370 63380815
Pulmonary oedema 11.68 10.02 50 106787 54823 63327362
Knee arthroplasty 11.64 10.02 141 106696 54065 63328120
Meralgia paraesthetica 11.60 10.02 8 106829 443 63381742
Haemorrhagic diathesis 11.57 10.02 24 106813 4391 63377794
Asterixis 11.57 10.02 13 106824 1386 63380799
Cardiogenic shock 11.56 10.02 8 106829 17924 63364261
Neuroleptic malignant syndrome 11.56 10.02 3 106834 12053 63370132
Loss of consciousness 11.49 10.02 270 106567 117851 63264334
Night sweats 11.38 10.02 129 106708 48685 63333500
Drug reaction with eosinophilia and systemic symptoms 11.37 10.02 25 106812 33811 63348374
Influenza 11.35 10.02 251 106586 108471 63273714
Hepatitis 11.34 10.02 32 106805 39756 63342429
Pelvic adhesions 11.28 10.02 7 106830 324 63381861
Jaundice 11.21 10.02 20 106817 29231 63352954
Injection site warmth 11.20 10.02 53 106784 15142 63367043
Focal segmental glomerulosclerosis 11.06 10.02 13 106824 1455 63380730
Progressive multifocal leukoencephalopathy 11.04 10.02 4 106833 12967 63369218
Rheumatic fever 11.00 10.02 116 106721 42995 63339190
Aerophagia 10.99 10.02 3 106834 14 63382171
Generalised tonic-clonic seizure 10.98 10.02 20 106817 28996 63353189
Decreased eye contact 10.88 10.02 7 106830 345 63381840
Altered state of consciousness 10.85 10.02 16 106821 25214 63356971
Bacteraemia 10.84 10.02 8 106829 17340 63364845
Atopic keratoconjunctivitis 10.82 10.02 3 106834 15 63382170
Hypokalaemia 10.80 10.02 117 106720 103687 63278498
Skin necrosis 10.74 10.02 5 106832 13945 63368240
Peripheral venous disease 10.70 10.02 53 106784 15424 63366761
Manipulation 10.69 10.02 4 106833 58 63382127
Chromaturia 10.69 10.02 56 106781 16661 63365524
Transaminases increased 10.68 10.02 23 106814 31344 63350841
Rotator cuff syndrome 10.62 10.02 48 106789 13454 63368731
Food allergy 10.62 10.02 3 106834 11398 63370787
Neoplasm progression 10.60 10.02 29 106808 36399 63345786
Antinuclear antibody 10.50 10.02 8 106829 518 63381667
Hypoglycaemia 10.32 10.02 59 106778 60006 63322179
Seizure 10.29 10.02 159 106678 132475 63249710
Dandruff 10.23 10.02 6 106831 250 63381935
Product administration interrupted 10.10 10.02 24 106813 4812 63377373
Crystal nephropathy 10.06 10.02 10 106827 926 63381259
Wrist deformity 10.06 10.02 15 106822 2115 63380070
Therapeutic product effect decreased 10.04 10.02 409 106428 192778 63189407

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 210.06 11.73 205 28320 38607 34889799
Psoriatic arthropathy 115.40 11.73 109 28416 19689 34908717
Arthralgia 91.84 11.73 326 28199 169715 34758691
Gastric haemorrhage 82.86 11.73 68 28457 10193 34918213
Joint swelling 76.48 11.73 158 28367 59732 34868674
Pain 62.22 11.73 330 28195 204345 34724061
Ankylosing spondylitis 57.96 11.73 43 28482 5561 34922845
Lipoma 51.23 11.73 26 28499 1700 34926706
Off label use 49.73 11.73 176 28349 419348 34509058
Osteoarthritis 48.04 11.73 71 28454 20571 34907835
Musculoskeletal stiffness 46.98 11.73 112 28413 46568 34881838
Intestinal diaphragm disease 45.46 11.73 14 28511 235 34928171
Duodenal ulcer 43.94 11.73 48 28477 10284 34918122
Neutropenia 42.74 11.73 39 28486 156739 34771667
Febrile neutropenia 42.36 11.73 30 28495 136819 34791587
Pain in extremity 41.14 11.73 208 28317 126305 34802101
Seronegative arthritis 40.93 11.73 19 28506 1020 34927386
Back pain 40.14 11.73 201 28324 121588 34806818
Xyphoid retraction 37.06 11.73 11 28514 162 34928244
Exostosis 35.43 11.73 30 28495 4693 34923713
Product dose omission issue 34.24 11.73 190 28335 119521 34808885
Gastrointestinal haemorrhage 33.47 11.73 152 28373 88325 34840081
Thrombocytopenia 32.72 11.73 48 28477 156199 34772207
Gastric ulcer 32.42 11.73 51 28474 15599 34912807
Arthritis 32.39 11.73 76 28449 31270 34897136
Surgery 30.53 11.73 47 28478 14110 34914296
Drug ineffective 29.04 11.73 528 27997 456223 34472183
Foot deformity 28.39 11.73 26 28499 4511 34923895
Sinusitis 27.26 11.73 85 28440 41317 34887089
Oesophageal infection 27.06 11.73 10 28515 299 34928107
General physical health deterioration 26.27 11.73 40 28485 128229 34800177
Tendon disorder 25.21 11.73 20 28505 2855 34925551
Rheumatoid arthritis 24.71 11.73 78 28447 38160 34890246
Foot fracture 24.36 11.73 25 28500 4986 34923420
Injection site erythema 23.96 11.73 45 28480 15854 34912552
Oropharyngeal pain 23.49 11.73 73 28452 35412 34892994
Ankle fracture 22.67 11.73 22 28503 4103 34924303
Arthropathy 22.30 11.73 60 28465 26847 34901559
Multiple organ dysfunction syndrome 22.11 11.73 18 28507 76548 34851858
Joint stiffness 21.92 11.73 35 28490 10838 34917568
Arthrofibrosis 21.57 11.73 6 28519 69 34928337
Mobility decreased 19.96 11.73 62 28463 30066 34898340
Acute generalised exanthematous pustulosis 19.79 11.73 26 28499 6750 34921656
Fixed eruption 19.76 11.73 14 28511 1686 34926720
Neck pain 19.49 11.73 55 28470 25294 34903112
Hip arthroplasty 19.38 11.73 21 28504 4458 34923948
Ascites 19.18 11.73 7 28518 46564 34881842
Leukopenia 19.14 11.73 14 28511 62842 34865564
Inflammatory marker increased 19.05 11.73 22 28503 5006 34923400
Epstein Barr virus positive mucocutaneous ulcer 18.38 11.73 8 28517 369 34928037
Cartilage injury 18.31 11.73 9 28516 549 34927857
Disease progression 18.24 11.73 38 28487 108039 34820367
Musculoskeletal discomfort 17.70 11.73 27 28498 8041 34920365
Duodenal ulcer haemorrhage 17.45 11.73 21 28504 4992 34923414
Hernia 16.84 11.73 29 28496 9554 34918852
Finger deformity 16.53 11.73 12 28513 1501 34926905
Peripheral swelling 16.50 11.73 113 28412 76428 34851978
Hypokalaemia 16.42 11.73 14 28511 58200 34870206
Macrophages increased 16.41 11.73 6 28519 174 34928232
Cellulitis gangrenous 16.00 11.73 6 28519 187 34928219
Fatigue 15.88 11.73 405 28120 370248 34558158
Feeling abnormal 15.86 11.73 97 28428 63138 34865268
Headache 15.62 11.73 240 28285 200395 34728011
Skin exfoliation 15.08 11.73 53 28472 27379 34901027
Knee arthroplasty 15.06 11.73 24 28501 7420 34920986
Skin ulcer 14.98 11.73 46 28479 22170 34906236
Intervertebral disc protrusion 14.78 11.73 28 28497 9928 34918478
Iritis 14.77 11.73 11 28514 1430 34926976
Neck surgery 14.74 11.73 7 28518 396 34928010
Electrocardiogram QRS complex prolonged 14.63 11.73 19 28506 4875 34923531
Loose body in joint 14.63 11.73 4 28521 43 34928363
Sleep apnoea syndrome 14.57 11.73 43 28482 20278 34908128
Drug hypersensitivity 14.56 11.73 114 28411 80415 34847991
Insomnia 14.55 11.73 139 28386 103768 34824638
Water intoxication 14.34 11.73 7 28518 421 34927985
Acanthosis 14.33 11.73 5 28520 126 34928280
Eyelid margin crusting 14.29 11.73 6 28519 253 34928153
Pyrexia 14.24 11.73 189 28336 332824 34595582
Depression 14.15 11.73 131 28394 96967 34831439
Gastrointestinal injury 13.84 11.73 7 28518 454 34927952
Synovial cyst 13.83 11.73 13 28512 2331 34926075
Injection site bruising 13.65 11.73 25 28500 8638 34919768
Duodenal ulcer perforation 13.56 11.73 11 28514 1621 34926785
Uveitis 13.50 11.73 23 28502 7512 34920894
Gait disturbance 13.50 11.73 117 28408 85023 34843383
Prostatic specific antigen increased 13.46 11.73 34 28491 14646 34913760
Gastric perforation 13.03 11.73 13 28512 2507 34925899
Product physical issue 12.94 11.73 13 28512 2528 34925878
Rotator cuff repair 12.86 11.73 6 28519 326 34928080
Hypoaesthesia 12.82 11.73 90 28435 61354 34867052
Injection site haemorrhage 12.72 11.73 26 28499 9742 34918664
Electrocardiogram QT prolonged 12.62 11.73 9 28516 40943 34887463
Swelling 12.59 11.73 68 28457 42298 34886108
Pancytopenia 12.52 11.73 38 28487 95119 34833287
Lumbar radiculopathy 12.31 11.73 8 28517 836 34927570
Sacroiliitis 12.24 11.73 10 28515 1488 34926918
Completed suicide 12.14 11.73 128 28397 98040 34830366
Pulmonary tuberculosis 12.00 11.73 17 28508 4737 34923669
Dizziness 11.88 11.73 247 28278 218274 34710132
Oxygen saturation 11.86 11.73 5 28520 213 34928193

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rheumatoid arthritis 247.49 10.42 717 104134 207753 79431784
Psoriatic arthropathy 229.88 10.42 387 104464 77612 79561925
Fibromyalgia 190.60 10.42 320 104531 64020 79575517
Synovial cyst 182.61 10.42 131 104720 9934 79629603
Psoriasis 177.36 10.42 375 104476 89212 79550325
Arthralgia 163.51 10.42 1297 103554 570506 79069031
Musculoskeletal stiffness 157.24 10.42 547 104304 174461 79465076
Ankylosing spondylitis 155.98 10.42 129 104722 12076 79627461
Surgical failure 155.36 10.42 54 104797 815 79638722
Febrile neutropenia 155.04 10.42 55 104796 230944 79408593
Neutropenia 152.41 10.42 95 104756 287615 79351922
Joint swelling 139.00 10.42 747 104104 287899 79351638
Drug hypersensitivity 128.94 10.42 751 104100 298165 79341372
Joint range of motion decreased 119.83 10.42 181 104670 33101 79606436
Vital capacity decreased 116.81 10.42 54 104797 1762 79637775
Tenosynovitis stenosans 116.76 10.42 64 104787 3014 79636523
Pain in extremity 114.63 10.42 846 104005 363692 79275845
Reversible airways obstruction 113.43 10.42 56 104795 2120 79637417
Death 109.08 10.42 381 104470 566133 79073404
Bursitis 108.43 10.42 180 104671 35664 79603873
Synovial fluid analysis 106.26 10.42 55 104796 2304 79637233
Thrombocytopenia 103.15 10.42 118 104733 265141 79374396
Pain 101.53 10.42 1389 103462 702413 78937124
Musculoskeletal pain 99.86 10.42 329 104522 102025 79537512
Spinal column injury 98.30 10.42 51 104800 2147 79637390
Bronchitis chronic 96.95 10.42 65 104786 4417 79635120
Scleritis 91.42 10.42 62 104789 4294 79635243
Sputum culture positive 89.48 10.42 58 104793 3723 79635814
Bone density decreased 88.14 10.42 98 104753 13249 79626288
Neck pain 87.03 10.42 257 104594 75160 79564377
Dry eye 84.23 10.42 164 104687 36767 79602770
Hypotension 84.09 10.42 297 104554 440020 79199517
Osteoarthritis 81.04 10.42 276 104575 87033 79552504
Off label use 80.19 10.42 785 104066 906430 78733107
Sciatica 78.79 10.42 150 104701 33072 79606465
Bronchial secretion retention 78.10 10.42 55 104796 4049 79635488
Neck surgery 75.07 10.42 40 104811 1779 79637758
Acute kidney injury 73.73 10.42 392 104459 519012 79120525
Product dose omission issue 72.93 10.42 566 104285 246971 79392566
Pulmonary toxicity 72.15 10.42 87 104764 12827 79626710
Back pain 71.88 10.42 662 104189 303518 79336019
Tenosynovitis 71.38 10.42 95 104756 15459 79624078
Anaemia 71.13 10.42 322 104529 444693 79194844
Rheumatoid lung 69.65 10.42 52 104799 4193 79635344
Septic shock 68.56 10.42 38 104813 122763 79516774
Peripheral swelling 65.83 10.42 591 104260 269026 79370511
Deep vein thrombosis postoperative 64.31 10.42 75 104776 10677 79628860
Accident 63.82 10.42 68 104783 8763 79630774
Crepitations 63.49 10.42 72 104779 9945 79629592
Pancytopenia 63.03 10.42 75 104776 165670 79473867
Antinuclear antibody positive 62.84 10.42 64 104787 7826 79631711
Drug abuse 62.52 10.42 73 104778 162618 79476919
Multiple organ dysfunction syndrome 61.83 10.42 41 104810 120205 79519332
Allergy to chemicals 59.34 10.42 39 104812 2563 79636974
Autoimmune disorder 59.30 10.42 90 104761 16522 79623015
Toxicity to various agents 59.30 10.42 319 104532 421221 79218316
Mobility decreased 58.55 10.42 316 104535 121859 79517678
Dry mouth 58.37 10.42 250 104601 87769 79551768
Feeling jittery 58.27 10.42 78 104773 12763 79626774
Cushingoid 56.08 10.42 66 104785 9486 79630051
Impaired work ability 55.76 10.42 96 104755 19585 79619952
Drug interaction 55.23 10.42 320 104531 414863 79224674
Pleuritic pain 54.45 10.42 67 104784 10085 79629452
Photophobia 54.10 10.42 97 104754 20431 79619106
Joint effusion 53.85 10.42 90 104761 17924 79621613
Pyrexia 53.43 10.42 603 104248 678106 78961431
Disease progression 53.08 10.42 101 104750 184261 79455276
Cardiac failure 52.78 10.42 76 104775 154766 79484771
Visual impairment 52.35 10.42 250 104601 91881 79547656
Drug ineffective 52.11 10.42 1820 103031 1079093 78560444
Upper-airway cough syndrome 51.49 10.42 70 104781 11623 79627914
Swollen joint count increased 51.29 10.42 101 104750 22826 79616711
Tenderness 50.31 10.42 102 104749 23540 79615997
Rheumatic fever 50.27 10.42 114 104737 28411 79611126
Nodule 49.88 10.42 100 104751 22894 79616643
Multiple allergies 49.72 10.42 65 104786 10395 79629142
Gait disturbance 49.67 10.42 453 104398 207053 79432484
Blood cholesterol increased 49.63 10.42 230 104621 83490 79556047
Feeling abnormal 49.07 10.42 368 104483 158831 79480706
Arthritis 49.00 10.42 288 104563 114592 79524945
Drug intolerance 48.53 10.42 546 104305 263573 79375964
Linear IgA disease 48.36 10.42 37 104814 3095 79636442
Malignant neoplasm progression 48.09 10.42 65 104786 135925 79503612
Therapeutic product effect decreased 47.84 10.42 374 104477 163489 79476048
Grip strength decreased 47.31 10.42 95 104756 21774 79617763
Road traffic accident 46.79 10.42 145 104706 43519 79596018
Conjunctivitis 46.69 10.42 104 104747 25611 79613926
Hypoaesthesia 46.25 10.42 398 104453 178954 79460583
Hyponatraemia 45.66 10.42 104 104747 177744 79461793
Leukopenia 45.06 10.42 52 104799 116461 79523076
Intestinal diaphragm disease 44.82 10.42 17 104834 333 79639204
Sepsis 44.78 10.42 192 104659 269236 79370301
Viral upper respiratory tract infection 44.32 10.42 57 104794 8969 79630568
Injection site erythema 44.29 10.42 212 104639 77985 79561552
Arthropathy 44.10 10.42 390 104461 176721 79462816
Flank pain 43.88 10.42 87 104764 19757 79619780
Pulmonary mass 43.56 10.42 109 104742 28925 79610612
Gastric haemorrhage 43.41 10.42 74 104777 14976 79624561
Platelet count decreased 42.90 10.42 123 104728 194541 79444996
Eye irritation 42.56 10.42 88 104763 20593 79618944
Sinusitis 41.92 10.42 417 104434 195084 79444453
Gait inability 41.91 10.42 171 104680 58746 79580791
Gastric ulcer 41.47 10.42 118 104733 33787 79605750
General physical health deterioration 41.07 10.42 204 104647 275034 79364503
Injection site pain 40.50 10.42 301 104550 129537 79510000
C-reactive protein 38.95 10.42 40 104811 4939 79634598
Duodenal ulcer 38.92 10.42 74 104777 16295 79623242
Cardiogenic shock 38.12 10.42 5 104846 41909 79597628
Listless 37.66 10.42 35 104816 3826 79635711
X-ray abnormal 37.21 10.42 42 104809 5771 79633766
Depression 36.61 10.42 441 104410 216349 79423188
Lipoma 36.33 10.42 31 104820 3028 79636509
Injection site swelling 36.10 10.42 140 104711 46992 79592545
Cytokine release syndrome 36.07 10.42 3 104848 35995 79603542
Knee arthroplasty 36.05 10.42 132 104719 43116 79596421
Tachycardia 35.84 10.42 117 104734 177651 79461886
Pleural effusion 35.64 10.42 87 104764 145175 79494362
Mucosal inflammation 34.68 10.42 29 104822 75551 79563986
Prescribed overdose 34.47 10.42 119 104732 37764 79601773
Ocular hyperaemia 34.33 10.42 98 104753 28108 79611429
Drug resistance 34.02 10.42 7 104844 42206 79597331
Musculoskeletal discomfort 33.55 10.42 78 104773 19757 79619780
Adjustment disorder with depressed mood 33.53 10.42 50 104801 9036 79630501
Neoplasm malignant 33.49 10.42 105 104746 31705 79607832
Intervertebral disc degeneration 33.46 10.42 68 104783 15717 79623820
Electrocardiogram QT prolonged 33.19 10.42 42 104809 90344 79549193
Respiratory failure 33.15 10.42 124 104727 180787 79458750
Somatic delusion 33.09 10.42 17 104834 701 79638836
Hypoxia 32.93 10.42 53 104798 103190 79536347
Blood creatinine increased 32.69 10.42 100 104751 154957 79484580
Xyphoid retraction 31.89 10.42 11 104840 162 79639375
Myelosuppression 31.82 10.42 7 104844 40289 79599248
Hyperkalaemia 31.76 10.42 64 104787 114334 79525203
Cytomegalovirus infection 30.62 10.42 9 104842 42635 79596902
Carpal tunnel syndrome 30.02 10.42 74 104777 19454 79620083
Injection site bruising 29.95 10.42 120 104731 40882 79598655
Muscular weakness 29.82 10.42 333 104518 160396 79479141
Agranulocytosis 29.70 10.42 11 104840 45019 79594518
Lower limb fracture 29.57 10.42 82 104769 23133 79616404
International normalised ratio increased 29.44 10.42 41 104810 84680 79554857
Neurotoxicity 29.29 10.42 4 104847 32514 79607023
Fixed eruption 29.24 10.42 27 104824 2927 79636610
Injection site reaction 29.21 10.42 146 104705 54639 79584898
Ascites 28.91 10.42 34 104817 75528 79564009
Injury 28.47 10.42 187 104664 77309 79562228
Hypermobility syndrome 28.40 10.42 14 104837 528 79639009
Rhabdomyolysis 28.37 10.42 58 104793 103073 79536464
Injection site vesicles 28.34 10.42 27 104824 3045 79636492
Bradycardia 28.17 10.42 88 104763 135469 79504068
Cholestasis 27.83 10.42 17 104834 52092 79587445
Memory impairment 27.77 10.42 246 104605 111488 79528049
Arthrofibrosis 27.70 10.42 9 104842 109 79639428
Neutrophil count decreased 26.57 10.42 52 104799 93907 79545630
Lip dry 26.48 10.42 61 104790 15357 79624180
Product use in unapproved indication 26.23 10.42 207 104644 250152 79389385
Hepatocellular injury 26.16 10.42 15 104836 47578 79591959
Treatment failure 25.86 10.42 340 104511 170146 79469391
Rheumatoid nodule 25.67 10.42 65 104786 17373 79622164
Hip arthroplasty 25.60 10.42 104 104747 35652 79603885
Hypoglycaemia 25.58 10.42 60 104791 101534 79538003
Bone marrow failure 25.50 10.42 18 104833 51089 79588448
Contusion 25.26 10.42 303 104548 148473 79491064
Seronegative arthritis 25.22 10.42 31 104820 4661 79634876
Blood bilirubin increased 25.13 10.42 30 104821 66202 79573335
Therapy cessation 25.13 10.42 107 104744 37455 79602082
Intentional self-injury 24.87 10.42 6 104845 32413 79607124
Intentional overdose 24.79 10.42 65 104786 105895 79533642
Clostridium difficile colitis 24.71 10.42 6 104845 32277 79607260
Pneumonia aspiration 24.71 10.42 31 104820 66936 79572601
Syncope 24.52 10.42 137 104714 179312 79460225
Eosinophil count increased 24.39 10.42 63 104788 17042 79622495
Hypokalaemia 24.31 10.42 102 104749 143938 79495599
Spinal operation 24.26 10.42 40 104811 7877 79631660
Posterior reversible encephalopathy syndrome 24.23 10.42 3 104848 26278 79613259
Wound infection 24.17 10.42 78 104773 23913 79615624
Eosinophilia 23.93 10.42 15 104836 45330 79594207
Foot fracture 23.55 10.42 73 104778 21908 79617629
Headache 23.43 10.42 1067 103784 652705 78986832
Head discomfort 23.41 10.42 56 104795 14446 79625091
Infection 23.36 10.42 447 104404 241265 79398272
Wheezing 23.16 10.42 245 104606 116419 79523118
Night sweats 23.11 10.42 132 104719 51963 79587574
Abdominal pain upper 23.05 10.42 418 104433 223401 79416136
Eye pain 22.83 10.42 104 104747 37474 79602063
Small intestinal stenosis 22.74 10.42 14 104837 821 79638716
Respiratory distress 22.59 10.42 26 104825 58313 79581224
Ischaemic gastritis 22.38 10.42 5 104846 11 79639526
Haematuria 22.27 10.42 35 104816 68801 79570736
Sputum culture 21.99 10.42 9 104842 217 79639320
Hepatic failure 21.89 10.42 29 104822 61183 79578354
Iritis 21.58 10.42 26 104825 3829 79635708
Limb asymmetry 21.44 10.42 12 104839 589 79638948
Hypercalcaemia 21.29 10.42 12 104839 38418 79601119
Eyelid retraction 21.03 10.42 6 104845 45 79639492
Urine odour abnormal 21.01 10.42 33 104818 6240 79633297
Right ventricular failure 20.90 10.42 3 104848 23494 79616043
Muscle spasms 20.77 10.42 334 104517 174396 79465141
Anxiety 20.53 10.42 449 104402 248063 79391474
Sacroiliitis 20.50 10.42 25 104826 3729 79635808
Lung disorder 20.35 10.42 178 104673 80379 79559158
Tendon disorder 20.28 10.42 35 104816 7151 79632386
Upper respiratory tract infection 20.27 10.42 196 104655 90972 79548565
Sedation 20.23 10.42 23 104828 51872 79587665
Synovitis 20.17 10.42 294 104557 150440 79489097
Poliomyelitis 19.87 10.42 6 104845 56 79639481
Joint stiffness 19.81 10.42 106 104745 40724 79598813
Therapeutic product effect incomplete 19.64 10.42 278 104573 141367 79498170
Pneumonitis 19.64 10.42 31 104820 60829 79578708
Walking aid user 19.51 10.42 42 104809 10106 79629431
Reduced facial expression 19.47 10.42 21 104830 2744 79636793
Aggression 19.42 10.42 23 104828 50935 79588602
Surgery 19.40 10.42 90 104761 32676 79606861
Atelectasis 19.39 10.42 89 104762 32168 79607369
Synovial disorder 19.39 10.42 18 104833 1965 79637572
Cataract 19.35 10.42 144 104707 61976 79577561
Renal failure 19.30 10.42 170 104681 200798 79438739
Suicide attempt 19.30 10.42 51 104800 82881 79556656
Tumour lysis syndrome 19.23 10.42 4 104847 23935 79615602
Blood creatine phosphokinase increased 19.19 10.42 36 104815 66054 79573483
Oropharyngeal pain 19.12 10.42 224 104627 109129 79530408
Intervertebral disc protrusion 18.77 10.42 71 104780 23550 79615987
Injection site pruritus 18.66 10.42 107 104744 42176 79597361
Oedema peripheral 18.66 10.42 227 104624 252061 79387476
Liver injury 18.65 10.42 133 104718 56481 79583056
Lymphomatoid papulosis 18.15 10.42 9 104842 344 79639193
Manipulation 18.08 10.42 6 104845 78 79639459
Cerebral haemorrhage 18.02 10.42 30 104821 57643 79581894
Seizure 18.02 10.42 160 104691 188674 79450863
Breast cancer 17.98 10.42 90 104761 33691 79605846
Ankle fracture 17.85 10.42 56 104795 16913 79622624
Neuroleptic malignant syndrome 17.73 10.42 7 104844 27552 79611985
Cardiac failure congestive 17.71 10.42 112 104739 142290 79497247
Malaise 17.62 10.42 800 104051 489069 79150468
Deformity 17.61 10.42 39 104812 9566 79629971
Discomfort 17.60 10.42 247 104604 125370 79514167
Epistaxis 17.58 10.42 81 104770 111434 79528103
Type 2 diabetes mellitus 17.56 10.42 132 104719 56990 79582547
Hepatic encephalopathy 17.53 10.42 5 104846 24161 79615376
Ejection fraction decreased 17.49 10.42 12 104839 34565 79604972
Migraine 17.48 10.42 184 104667 87309 79552228
Exposure during pregnancy 17.44 10.42 71 104780 101061 79538476
Rash pruritic 17.43 10.42 157 104694 71472 79568065
Bronchopulmonary aspergillosis 17.35 10.42 4 104847 22290 79617247
Liver disorder 17.25 10.42 158 104693 72259 79567278
Exostosis 17.15 10.42 55 104796 16803 79622734
Bacteraemia 17.13 10.42 11 104840 32813 79606724
Knee operation 17.12 10.42 29 104822 5837 79633700
Cartilage injury 17.04 10.42 15 104836 1528 79638009
Pulmonary arterial hypertension 16.99 10.42 8 104843 28358 79611179
C-reactive protein abnormal 16.73 10.42 115 104736 48252 79591285
Abortion spontaneous 16.65 10.42 9 104842 29498 79610039
Loss of personal independence in daily activities 16.57 10.42 207 104644 102373 79537164
Duodenal ulcer perforation 16.56 10.42 146 104705 66065 79573472
Oesophageal mucosal tear 16.33 10.42 4 104847 15 79639522
Dehydration 16.27 10.42 229 104622 247958 79391579
Vertigo 16.09 10.42 150 104701 68932 79570605
Ulcer 16.06 10.42 80 104771 29892 79609645
Delirium 15.99 10.42 176 104675 84451 79555086
Nodular rash 15.96 10.42 8 104843 313 79639224
Orthostatic hypotension 15.95 10.42 31 104820 56133 79583404
Body temperature increased 15.93 10.42 21 104830 44399 79595138
Cardiac arrest 15.90 10.42 147 104704 171949 79467588
Aspergillus infection 15.81 10.42 3 104848 19158 79620379
Subdural haematoma 15.77 10.42 11 104840 31423 79608114
Dysphagia 15.74 10.42 95 104756 122041 79517496
Injection site warmth 15.70 10.42 49 104802 14758 79624779
Appendicitis 15.66 10.42 4 104847 20790 79618747
Facet joint syndrome 15.47 10.42 41 104810 11261 79628276
Live birth 15.44 10.42 57 104794 18687 79620850
Progressive multifocal leukoencephalopathy 15.44 10.42 4 104847 20596 79618941
Altered state of consciousness 15.43 10.42 21 104830 43801 79595736
Hepatic cirrhosis 15.28 10.42 14 104837 34892 79604645
Hand deformity 15.23 10.42 206 104645 103713 79535824
Transaminases increased 15.18 10.42 28 104823 51715 79587822
Trigger finger 15.15 10.42 23 104828 4222 79635315
Oesophageal infection 15.12 10.42 10 104841 664 79638873
Breast cancer stage II 14.92 10.42 33 104818 8087 79631450
Hepatotoxicity 14.88 10.42 28 104823 51324 79588213
Dizziness 14.87 10.42 840 104011 525601 79113936
Ventricular tachycardia 14.86 10.42 20 104831 41915 79597622
Device related infection 14.72 10.42 14 104837 34280 79605257
Tarsal tunnel syndrome 14.63 10.42 9 104842 527 79639010
Hyperbilirubinaemia 14.55 10.42 7 104844 24511 79615026
Dystonia 14.50 10.42 5 104846 21394 79618143
Pelvic fracture 14.46 10.42 42 104809 12162 79627375
Dislocation of vertebra 14.45 10.42 32 104819 7848 79631689
Finger deformity 14.44 10.42 31 104820 7443 79632094
Proteinuria 14.27 10.42 13 104838 32489 79607048
Foot deformity 14.16 10.42 66 104785 24008 79615529
Hepatic function abnormal 14.12 10.42 49 104802 73058 79566479
Demyelination 14.06 10.42 32 104819 7991 79631546
Fatigue 14.02 10.42 1411 103440 928316 78711221
Rheumatoid factor positive 13.97 10.42 130 104721 59709 79579828
Pulmonary oedema 13.97 10.42 64 104787 88190 79551347
Cellulitis gangrenous 13.91 10.42 7 104844 276 79639261
Aspartate aminotransferase increased 13.88 10.42 116 104735 138525 79501012
Stress fracture 13.84 10.42 28 104823 6452 79633085
Bipolar disorder 13.80 10.42 31 104820 7676 79631861
Thalassaemia minor 13.80 10.42 4 104847 32 79639505
Foreign body 13.78 10.42 18 104833 2876 79636661
Ventricular fibrillation 13.74 10.42 13 104838 31913 79607624
Hyperglycaemia 13.68 10.42 47 104804 70288 79569249
Pelvic adhesions 13.62 10.42 7 104844 289 79639248
Impaired gastric emptying 13.61 10.42 37 104814 10316 79629221
Symptom recurrence 13.60 10.42 16 104835 2298 79637239
Porphyria acute 13.23 10.42 13 104838 1522 79638015
Antinuclear antibody 13.15 10.42 8 104843 459 79639078
Pharyngeal paraesthesia 13.07 10.42 17 104834 2704 79636833
Wrist deformity 13.05 10.42 15 104836 2102 79637435
Sleep disorder 13.04 10.42 171 104680 85506 79554031
Colitis 12.93 10.42 51 104800 73256 79566281
Lung infiltration 12.91 10.42 7 104844 22905 79616632
Metastases to liver 12.82 10.42 11 104840 28303 79611234
Peripheral venous disease 12.79 10.42 48 104803 15861 79623676
Skin necrosis 12.65 10.42 4 104847 18083 79621454
Affect lability 12.63 10.42 38 104813 11221 79628316
Respiratory tract infection 12.51 10.42 108 104743 48581 79590956
Swelling face 12.50 10.42 146 104705 71066 79568471
Purpura 12.50 10.42 5 104846 19522 79620015
Anuria 12.42 10.42 6 104845 20957 79618580
Hypomagnesaemia 12.38 10.42 27 104824 46884 79592653
Arthritis infective 12.35 10.42 31 104820 8240 79631297
Small intestinal ulcer haemorrhage 12.32 10.42 5 104846 118 79639419
Abnormal behaviour 12.28 10.42 18 104833 36403 79603134
Jaundice 12.27 10.42 33 104818 53316 79586221
Purpura senile 12.22 10.42 8 104843 522 79639015
Splenomegaly 12.20 10.42 6 104845 20748 79618789
Anhidrosis 12.18 10.42 6 104845 226 79639311
Alanine aminotransferase increased 12.12 10.42 146 104705 162424 79477113
Haemorrhage intracranial 12.08 10.42 10 104841 26183 79613354
Accidental overdose 11.99 10.42 21 104830 39560 79599977
Back disorder 11.99 10.42 38 104813 11540 79627997
Spinal osteoarthritis 11.93 10.42 49 104802 16878 79622659
Neoplasm progression 11.86 10.42 32 104819 51650 79587887
Illness 11.86 10.42 103 104748 46408 79593129
Drug eruption 11.83 10.42 25 104826 43910 79595627
Poisoning deliberate 11.76 10.42 5 104846 18823 79620714
Rotator cuff syndrome 11.73 10.42 43 104808 14052 79625485
Hepatitis 11.70 10.42 36 104815 55691 79583846
Dandruff 11.66 10.42 7 104844 392 79639145
Product prescribing error 11.66 10.42 26 104825 44787 79594750
Pulmonary hypertension 11.62 10.42 29 104822 48051 79591486
Spinal fusion surgery 11.62 10.42 23 104828 5215 79634322
Influenza 11.61 10.42 237 104614 129369 79510168
Adverse drug reaction 11.60 10.42 136 104715 66256 79573281
Obstructive airways disorder 11.60 10.42 76 104775 31383 79608154
Ligament rupture 11.57 10.42 18 104833 3376 79636161
Limb operation 11.44 10.42 18 104833 3408 79636129
Lymphopenia 11.42 10.42 14 104837 30543 79608994
Circulatory collapse 11.40 10.42 20 104831 37648 79601889
Muscle rigidity 11.31 10.42 6 104845 19876 79619661
Cervical radiculopathy 11.30 10.42 11 104840 1274 79638263
Barrett's oesophagus 11.28 10.42 9 104842 800 79638737
Gastrointestinal haemorrhage 11.28 10.42 264 104587 147455 79492082
Chromaturia 11.26 10.42 65 104786 25681 79613856
Blister 11.21 10.42 220 104631 119256 79520281
Gastric mucosal hypertrophy 11.20 10.42 6 104845 270 79639267
Dyspepsia 11.18 10.42 203 104648 108484 79531053
Alopecia 11.14 10.42 390 104461 230965 79408572
Macrophages increased 11.09 10.42 6 104845 275 79639262
Overdose 11.01 10.42 173 104678 184033 79455504
Skin ulcer 10.87 10.42 114 104737 54036 79585501
Duodenal ulcer haemorrhage 10.86 10.42 27 104824 7136 79632401
Vaginal neoplasm 10.81 10.42 4 104847 73 79639464
Left ventricular dysfunction 10.79 10.42 6 104845 19355 79620182
Autoimmune hepatitis 10.71 10.42 37 104814 11746 79627791
Tachypnoea 10.66 10.42 16 104835 32047 79607490
Menopausal symptoms 10.60 10.42 13 104838 1950 79637587
Encephalopathy 10.59 10.42 49 104802 67348 79572189
Dyspnoea exertional 10.56 10.42 69 104782 87004 79552533
Paraesthesia 10.52 10.42 305 104546 176018 79463519
Diabetic ketoacidosis 10.43 10.42 18 104833 34104 79605433
Creatinine renal clearance decreased 10.43 10.42 6 104845 18996 79620541

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AC06 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Oxicams
ATC M01AC56 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Oxicams
ATC N01BB59 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
FDA CS M0001335 Anti-Inflammatory Agents, Non-Steroidal
FDA MoA N0000000160 Cyclooxygenase Inhibitors
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D052246 Cyclooxygenase 2 Inhibitors
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:35842 anti-rheumatic drugs
CHEBI has role CHEBI:50629 COX-2 inhibitor
FDA EPC N0000175722 Nonsteroidal Anti-inflammatory Drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Rheumatoid arthritis indication 69896004 DOID:7148
Osteoarthritis indication 396275006
Juvenile rheumatoid arthritis indication 410795001
Ankylosing spondylitis off-label use 9631008 DOID:7147
Gastritis contraindication 4556007 DOID:4029
Alcoholism contraindication 7200002
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Gastrointestinal perforation contraindication 51875005
Hyperlipidemia contraindication 55822004 DOID:1168
Blood coagulation disorder contraindication 64779008 DOID:1247
Aortocoronary artery bypass graft contraindication 67166004
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Coronary artery bypass graft contraindication 232717009
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Smokes tobacco daily contraindication 449868002




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Postoperative pain and inflammation associated with orthopedic surgery Indication
Cats Postoperative pain and inflammation associated with ovariohysterectomy Indication
Cats Postoperative pain and inflammation associated with castration Indication
Dogs Pain and inflammation associated with osteoarthritis Indication

🐶 Veterinary products

ProductApplicantIngredients
Metacam Oral Suspension Boehringer lngelheim Animal Health USA Inc. 1
Metacam 5 mg/mL Solution for Injection Boehringer lngelheim Animal Health USA Inc. 1
OroCAM Transmucosal Oral Spray Zoetis Inc. 1
Meloxicam Injection Accord Healthcare Inc. 1
Loxicom Norbrook Laboratories, Ltd. 1
Loxicom Norbrook Laboratories, Ltd. 1
Meloxicam Solution for Injection Dechra Veterinary Products LLC 1
Meloxidyl Ceva Sante Animale 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.65 acidic
pKa2 5.42 acidic
pKa3 4.32 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 DISCN SOLUTION INTRAVENOUS 10463673 Feb. 24, 2024 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 DISCN SOLUTION INTRAVENOUS 10471067 Feb. 24, 2024 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 DISCN SOLUTION INTRAVENOUS 10709713 May 26, 2030 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 DISCN SOLUTION INTRAVENOUS 11253478 May 26, 2030 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIVLODEX ICEUTICA OPERATIONS N207233 Oct. 22, 2015 DISCN CAPSULE ORAL 9808468 March 31, 2035 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIVLODEX ICEUTICA OPERATIONS N207233 Oct. 22, 2015 DISCN CAPSULE ORAL 9808468 March 31, 2035 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM
5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIVLODEX ICEUTICA OPERATIONS N207233 Oct. 22, 2015 DISCN CAPSULE ORAL 9808468 March 31, 2035 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIVLODEX ICEUTICA OPERATIONS N207233 Oct. 22, 2015 DISCN CAPSULE ORAL 9808468 March 31, 2035 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11413350 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11413350 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11413350 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11413350 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 DISCN SOLUTION INTRAVENOUS 10881663 March 8, 2039 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 DISCN SOLUTION INTRAVENOUS 11458145 March 8, 2039 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 DISCN SOLUTION INTRAVENOUS Feb. 20, 2023 NEW PRODUCT
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR May 12, 2024 NEW PRODUCT
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR May 12, 2024 NEW PRODUCT
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR May 12, 2024 NEW PRODUCT
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR May 12, 2024 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 6.80 CHEMBL CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 5.85 CHEMBL
Prostaglandin G/H synthase 2 Enzyme IC50 6.82 CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 6 CHEMBL
Prostaglandin G/H synthase 2 Enzyme IC50 5.86 CHEMBL

External reference:

IDSource
4021203 VUID
N0000148649 NUI
D00969 KEGG_DRUG
4021203 VANDF
C0083381 UMLSCUI
CHEBI:6741 CHEBI
MXM PDB_CHEM_ID
CHEMBL599 ChEMBL_ID
DB00814 DRUGBANK_ID
D000077239 MESH_DESCRIPTOR_UI
54677470 PUBCHEM_CID
7220 IUPHAR_LIGAND_ID
5615 INN_ID
VG2QF83CGL UNII
1086708 RXNORM
84146 MMSL
8839 MMSL
d04532 MMSL
006272 NDDF
125694008 SNOMEDCT_US
387055000 SNOMEDCT_US
CHEMBL1256873 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 0440-5841 TABLET 7.50 mg ORAL ANDA 28 sections
Mobic HUMAN PRESCRIPTION DRUG LABEL 1 0597-0029 TABLET 7.50 mg ORAL NDA 28 sections
Mobic HUMAN PRESCRIPTION DRUG LABEL 1 0597-0029 TABLET 7.50 mg ORAL NDA 28 sections
Mobic HUMAN PRESCRIPTION DRUG LABEL 1 0597-0030 TABLET 15 mg ORAL NDA 28 sections
Mobic HUMAN PRESCRIPTION DRUG LABEL 1 0597-0030 TABLET 15 mg ORAL NDA 28 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 0615-8040 TABLET 7.50 mg ORAL ANDA 26 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 0615-8040 TABLET 7.50 mg ORAL ANDA 26 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 0615-8040 TABLET 7.50 mg ORAL ANDA 26 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 0615-8124 TABLET 15 mg ORAL ANDA 26 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 0615-8124 TABLET 15 mg ORAL ANDA 26 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 0615-8124 TABLET 15 mg ORAL ANDA 26 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-052 TABLET 15 mg ORAL ANDA 31 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-090 TABLET 7.50 mg ORAL ANDA 31 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-251 TABLET 15 mg ORAL ANDA 27 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-252 TABLET 7.50 mg ORAL ANDA 27 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-555 TABLET 15 mg ORAL ANDA 25 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-631 TABLET 7.50 mg ORAL ANDA 25 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-925 TABLET 15 mg ORAL ANDA 26 sections
Meloxicam Human Prescription Drug Label 1 16571-776 TABLET 7.50 mg ORAL ANDA 28 sections
Meloxicam Human Prescription Drug Label 1 16571-777 TABLET 15 mg ORAL ANDA 28 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 16590-434 TABLET 7.50 mg ORAL ANDA 18 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 16590-469 TABLET 15 mg ORAL ANDA 18 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 21695-076 TABLET 7.50 mg None ANDA 26 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 21695-077 TABLET 15 mg ORAL ANDA 26 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 29300-124 TABLET 7.50 mg ORAL ANDA 27 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 29300-125 TABLET 15 mg ORAL ANDA 27 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 31722-226 TABLET 7.50 mg ORAL ANDA 20 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 31722-227 TABLET 15 mg ORAL ANDA 20 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 33261-070 TABLET 7.50 mg ORAL ANDA 25 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 33261-071 TABLET 15 mg ORAL ANDA 25 sections